Loading
NASDAQHealthcareBiotechnology
Latest quote
$8.26
+$0.33 · +4.16%
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
Latest quote
$8.26
+$0.33 · +4.16%
After-hours
$8.56
+$0.30 · +3.63%
Oct 8, 7:50 PM ET
Regular session · ET · Market data may be delayed.
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
Day range
Current $8.26
52-week range
Current $8.26
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
51
Fair Value
Sentiment
62
Bullish
Risk
42
Elevated Risk
Momentum
37
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
Day range
Current $8.26
52-week range
Current $8.26
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$25.00
202.66% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI6.91M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM3.05M0.00%77.7B USD0.19%$277.57-0.05%
Vanguard Extended Market ETFVXF2.51M0.00%95.4B USD0.05%$233.13-0.15%
Vanguard Russell 2000 ETFVTWO1.1M0.01%18B USD0.06%$112.1-0.10%
iShares Russell 2000 Growth ETFIWO788.05K0.01%14.04B USD0.24%$353.47-0.53%
Schwab U.S. Small-Cap ETFSCHA681.63K0.00%21.7B USD0.03%$32.66+0.15%
iShares Micro-Cap ETFIWC371.69K0.03%1.32B USD0.60%$182.79-0.31%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM160K0.13%116.54M USD0.73%$15.90-0.44%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
